Related content

Rare mutations in non-small-cell lung cancer

By D’Arcangelo Manolo   D’Incecco Armida   Cappuzzo Federico  

Future Oncology, Vol. 9, Iss. 5, 2013-05 ,pp. : 699-711

Future Medicine

Access to resources Recommend Favorite

The different efficacy of gefitinib or erlotinib according to epidermal growth factor receptor exon 19 and exon 21 mutations in Korean non-small cell lung cancer patients

By Sun Jong-Mu   Won Young-Woong   Kim Seung   Kim Jung   Choi Yoon-La   Lee Jeeyun   Park Yeon   Ahn Jin   Park Keunchil   Ahn Myung-Ju  

Journal of Cancer Research and Clinical Oncology, Vol. 137, Iss. 4, 2011-04 ,pp. : 687-694

Springer Publishing Company

Access to resources Recommend Favorite

Lack of prognostic value of EGFR mutations in primary resected non-small cell lung cancer

By Lim Ken-Hong   Huang Ming-Jer   Liu Hung-Chang   Kuo Hsu-Tah   Tzen Chin-Yuan   Hsieh Ruey-Kuen  

Medical Oncology, Vol. 24, Iss. 4, 2007-12 ,pp. : 388-393

Humana Press, Inc

Access to resources Recommend Favorite

Impact of EGFR mutations on treatment of non-small cell lung cancer

By Johnson Bruce   Jackman David   Jänne Pasi  

Cancer Chemotherapy and Pharmacology, Vol. 58, Iss. 7, 2006-11 ,pp. : 5-9

Springer Publishing Company

Access to resources Recommend Favorite

Impact of EGFR mutations on treatment of non-small cell lung cancer

By Johnson Bruce   Jackman David   Jänne Pasi  

Cancer Chemotherapy and Pharmacology, Vol. 58, Iss. 1, 2006-11 ,pp. : 5-9

Springer Publishing Company

Access to resources Recommend Favorite